Level A· Stronger Clinical EvidenceRandomized Controlled TrialPubMed

Autologous Cell Injections for Knee Osteoarthritis Display Greater Responsiveness Than Allogenic Cellular Products and Corticosteroids in a Sex-Dependent Manner.

Mautner K., Kaiser JM., Boggess B., Hackel J., Kurtenbach C., Noonan B.

Randomized Controlled Trial with a reported sample of 480 on Knee Osteoarthritis, Osteoarthritis, published in Am J Sports Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Am J Sports Med (2025)
Country
United States
Reported sample size
480
Source database
PubMed
PMID
41014273
DOI
10.1177/03635465251365521
NCT
NCT03818737

Abstract (original English)

Background Age-related knee osteoarthritis (KOA) is a debilitating and progressive whole-joint disease. Despite the increased use of cell-based therapies in clinical practice to alleviate KOA symptoms, there lacks robust evidence to guide their clinical utility. We recently reported the results of our randomized controlled trial comparing corticosteroid injections (CSI) to cell-based therapies of bone marrow aspirate concentrate (BMAC), stromal vascular fraction (SVF), and allogenic umbilical cord tissue in 480 patients with Kellgren-Lawrence grade 2 to 4 KOA, finding improvements in all groups at 1 year with no statistically significant differences between groups. Here, we further examine these data from our clinical trial using a responder/nonresponder approach. Hypothesis Patients receiving a single injection of a cell-based therapy are more likely to be classified as responders than those receiving a CSI based on pain outcomes at 12 months. Study design Randomized controlled trial; Level of evidence, 2. Methods We performed an analysis of 381 patients who completed 12 months' follow-up. Responders were defined as patients with a ≥25% improvement in pain scores on the visual analog scale (VAS) or Knee Injury and Osteoarthritis Outcome Score (KOOS). Results Our hypothesis was conditionally confirmed, with BMAC having a higher response rate than a CSI. The overall responder ra

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
HumansOsteoarthritis, KneeMaleFemaleMiddle AgedAdrenal Cortex HormonesAgedSex FactorsTransplantation, AutologousPain Measurement

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research